Clinical trials
Terminated Ovarian Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
380 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 5 |
| 2001 | 4 |
| 2002 | 5 |
| 2003 | 5 |
| 2004 | 9 |
| 2005 | 6 |
| 2006 | 16 |
| 2007 | 20 |
| 2008 | 9 |
| 2009 | 15 |
| 2010 | 15 |
| 2011 | 14 |
| 2012 | 10 |
| 2013 | 7 |
| 2014 | 14 |
| 2015 | 21 |
| 2016 | 17 |
| 2017 | 24 |
| 2018 | 21 |
| 2019 | 22 |
| 2020 | 22 |
| 2021 | 29 |
| 2022 | 21 |
| 2023 | 9 |
| 2024 | 14 |
| 2025 | 5 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 380 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Gynecologic Oncology Group | 18 |
| M.D. Anderson Cancer Center | 12 |
| National Cancer Institute (NCI) | 12 |
| Pfizer | 12 |
| Masonic Cancer Center, University of Minnesota | 8 |
| Dana-Farber Cancer Institute | 7 |
| Novartis Pharmaceuticals | 6 |
| Mayo Clinic | 5 |
| Seagen Inc. | 5 |
| Incyte Corporation | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ovarian Neoplasms | 380 |
| Fallopian Tube Neoplasms | 94 |
| Carcinoma, Ovarian Epithelial | 69 |
| Breast Neoplasms | 65 |
| Carcinoma, Non-Small-Cell Lung | 56 |
| Neoplasms | 39 |
| Colorectal Neoplasms | 37 |
| Endometrial Neoplasms | 37 |
| Melanoma | 31 |
| Pancreatic Neoplasms | 30 |
Trials
Showing 26 to 50 of 380. Each trial links to its page on Pharma Observatory.
280 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.